Aura Biosciences
AURA
49 hedge funds and large institutions have $250M invested in Aura Biosciences in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 6 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
14% more funds holding
Funds holding: 43 → 49 (+6)
10.31% more ownership
Funds ownership: 55.75% → 66.06% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less capital invested
Capital invested by funds: $296M → $250M (-$45.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$28.7M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$15.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.41M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.68M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$243K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$229K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$225K |
| 4 |
DTL
Dynamic Technology Lab
Singapore
|
-$217K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$161K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
UOC
51
UBS O'Connor
Chicago,
Illinois
| – | -$225K | -12,430 | Closed |
|
|
DTL
52
Dynamic Technology Lab
Singapore
| – | -$217K | -11,961 | Closed |
|
53
BNP Paribas Financial Markets
Paris,
France
| – | -$105K | -5,821 | Closed |
|
|
SO
54
STRS Ohio
Columbus,
Ohio
| – | -$23K | -1,300 | Closed |
|
55
Wells Fargo
San Francisco,
California
| – | -$6K | -310 | Closed |
|
AURA Hedge Fund Activity: Q4 2022 in Review
49 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q4 2022, worth a combined $250M — down 15% from $296M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AURA positions and 6 closed out — a net gain of 6 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $28.7M. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $243K sold.
- 49 institutional investors held Aura Biosciences (AURA) as of Q4 2022, up from 43 in Q3 2022.
- Funds reported $250M of Aura Biosciences stock for Q4 2022, down 15% quarter-over-quarter.
- 12 funds opened new Aura Biosciences positions in Q4 2022 and 6 closed out, a net change of +6 holders.
- The largest Aura Biosciences buyer in Q4 2022 was Eventide Asset Management, an estimated $28.7M added.
- The largest Aura Biosciences seller in Q4 2022 was CAPTRUST Financial Advisors, an estimated $243K sold.
Based on aggregated 13F filings for Q4 2022.